John R. LaMontagne Memorial Symposium on Pandemic Influenza Research April 4-5, 2005 Institute of Medicine Working Group Five: Immunology, Assay Standardization,

Slides:

Advertisements

Similar presentations

Duration of Serum Antibody Response to Seasonal Influenza Vaccines: Summary The level of antibody response made to seasonal influenza vaccines depends.

Advertisements

Licensing Pandemic Vaccines Novartis Vaccines Penny Heaton, MD, Global head clinical development clusters VRBPAC Washington DC, February 2012.

Avian and Pandemic Influenza Vaccine Development John Treanor Professor of Medicine University of Rochester Medical Center Rochester, NY.

Immunoprophylaxis (prophylactic immunization). Immunoprophylaxis Types of immunization Immunoglobulins and vaccines Strategies in vaccine preparation.

CAF01 adjuvant increases the protection conferred by a commercially available influenza split vaccine in a ferret model Introduction Desirable traits of.

Miriam Nuño Harvard School of Public Health, USA Gerardo Chowell Los Alamos National Laboratory, USA Abba Gumel University of Manitoba, Canada AIMS/DIMACS/SACEMA.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Avian Influenza - Pandemic Threat ? Reinhard Bornemann.

Medical Technology Department, Faculty of Science, Islamic University-Gaza MB M ICRO B IOLOGY Dr. Abdelraouf A. Elmanama Ph. D Microbiology 2008 Chapter.

National Vaccine Advisory Committee November 29, 2005 Update on NIH H5N1 Vaccine Trials Linda C. Lambert Chief, Respiratory Diseases Branch Division of.

6.4 B cells and humoral immunity

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.

New Monogram Biosciences Testing Capabilities: Influenza, RSV, Ebola and Other Respiratory and Enveloped Viruses.

Smallpox and Influenza "In early 1962 long queues attended any clinic in Birmingham offering vaccination, because three patients with smallpox were in.

EPIDEMIOLOGY AND PREVENTION OF INFLUENZA. Introduction Unique epidemiology: – Seasonal attack rates of 10% to 30% – Global epidemics Influenza viruses.

EPIDEMIOLOGY AND PREVENTION OF INFLUENZA. Introduction Unique epidemiology: – Seasonal attack rates of 10% to 30% – Global pandemics Influenza viruses.

Adaptive Immunity: Understanding cross-reactive responses Lorena E. Brown The University of Melbourne Australia.

Display of the Viral Epitopes on Lactococcus lactis: A Model for Food Grade Vaccine against EV71.

Making Vaccines.

Influenza Vaccine Development

Use of Immunogenicity Data to Assess Vaccine Effectiveness Cara R. Fiore, Ph D Microbiologist, Master Reviewer Office of Vaccines Research and Review Center.

Hugh B. Fackrell Filename: orthomyx.ppt

4th Year MPharm SRP: Introduction to Pseudotype Viruses

Copyright © 2009 Pearson Education Inc., publishing as Pearson Benjamin Cummings Chapter 17: Immunization and Immune Testing.

Copyright © 2009 Pearson Education Inc., publishing as Pearson Benjamin Cummings Chapter 17: Immunization and Immune Testing.

Viral Vaccine Types Viruses are inactivated with chemicals such as formaldehyde. Inactivated (killed) vaccines cannot cause an infection, but they.

“FluBlØk: A Recombinant Hemagglutinin Protein Vaccine for Influenza” Manon Cox VRBPAC February 27, 2007 A Vaccine Company for the 21st Century “Making.

ACKNOWLEDGMENTS USD Animal Resource Center Jonathan A. McCullers (St. Jude Children’s Research Hospital) for providing viruses SD-BRIN Undergraduate Fellows.

Neonatal Immunology Kristina Abel, PhD CNPRC UC Davis How a Lymphomaniac views ( IL )lness.

John R. LaMontagne Memorial Symposium on Pandemic Influenza Research April 4-5, 2005 Institute of Medicine Working Group One: Influenza Virulence and Antigenic.

Avian Influenza H5N1 Prepared by: Samia ALhabardi.

Effectiveness of Sub-capsular Meningococcal Vaccines An Approach to Evaluate Vaccines for the Prevention of Invasive Group B Meningococcal Disease VRBPAC.

Copyright © 2004 Pearson Education, Inc., publishing as Benjamin Cummings PowerPoint ® Lecture Slide Presentation prepared by Christine L. Case Microbiology.

Immunogenicity of combined vaccines in infants Helena Käyhty, PhD National Public Health Institute Dept of Vaccines Helsinki, Finland.

VRBPAC Topic #2: Clinical Development of Influenza Vaccines for Pre-pandemic Use Joseph G. Toerner, MD, MPH VCTB/DVRPA/OVRR/CBER/FDA February 27, 2007.

Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY.

Pandemic Vaccines Current and Future Issues 30 January 2007 Beijing Keiji Fukuda Global Influenza Programme.

It’s Just Not the Flu Anymore Rick Hong, MD Associate Chairman CCHS EMC Medical Director, PHPS.

1 INFLUENZA VIRUS. 2 ‘FLU’ True influenza –influenza virus A or influenza virus B (or influenza virus C infections - much milder) Febrile (showing signs.

John R. LaMontagne Memorial Symposium on Pandemic Influenza Research April 4-5, 2005 Institute of Medicine Working Group Two: Controlling Animal Influenza.

14. Immunodiagnosis, Immunotherapy & Vaccination 王家鑫， MD College of Veterinary Medicine.

25 Years of HIV Vaccine Research: What have we accomplished? José Esparza MD, PhD Senior Advisor on HIV Vaccines Global Health Program The Search for an.

Developing a Vaccine to Protect Against Pandemic Influenza Public Statement by GlaxoSmithKline 27 February 2007.

Making Vaccines. Effective Vaccines Have low levels of side effects or toxicity. Protect against exposure to natural, or wild forms of the pathogen. Should.

1 IMMUNE CORRELATES OF PROTECTION AGAINST INFLUENZA A VIRUSES IN SUPPORT OF PANDEMIC VACCINE DEVELOPMENT FDA/NIH/WHO Public Workshop, December 10-11, 2007.

“Neutralizing Antibodies Derived from the B Cells of 1918 Influenza Pandemic Survivors” (Yu et. al) Daniel Greenberg.

Quick Insights on Some Viral Issues Dr. Haya Al-Tawalah Clinical Virologist.

CATEGORY: VACCINES & THERAPEUTICS HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK HIV-1 Vaccines © The copyright for this work resides.

Vaccination Info. Journal of immunology Vaccination of HCWs was associated with reductions in total patient mortality from 17% to 10% (odds ratio [OR],

اختبارات التعادل المناعي:Neutralization Tests:

Design of randomized, double-blind, controlled, multi-center phase IIb trials as part of the EU- funded UNISEC project to assess the safety, immunogenicity.

Marketing Authorisation & Yearly Licence of Influenza Vaccines - „Mock-up” & Pre-Pandemic Influenza Vaccines Zsuzsanna Pauliny MD

1 Considerations in the Pre- and Early Pandemic Use of Influenza Vaccine Jesse L. Goodman, MD, MPH Center for Biologics Evaluation and Research, VRBPAC,

CVD Testing the H1N1 Pandemic Flu Vaccines Mini-Med School Karen Kotloff, MD University of Maryland School of Medicine Center for Vaccine Development September.

Viral vaccines .

Test of a new liposomal adjuvant for the commercial influenza vaccine in ferret Martel C. a, Hammer Jensen T. a, Viuff B. a, Nielsen L.P. b, Agger E.M.

I Introduction to influenza

I Introduction to influenza Department of Health 2016 Vaccination Campaign Training workshop Presentation developed by the National Institute for Communicable.

VIRAL INFLUENZA.

HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK

The more Effective FLU VACCINE PROBLEM

Scientific Challenges for the Development of an HIV Vaccine

The Body’s Defense Against Pathogens -- Memory

New Technologies in Vaccines

Objectives: Ch. 12 and 13 (host defenses)

? Neutralizing Antibodies: Research pathways in 2013 and beyond

Case presentation of non-clinical and clinical development of vaccines

A brief discussion on passive and active (esp., vaccines) immunity

Presentation transcript:

John R. LaMontagne Memorial Symposium on Pandemic Influenza Research April 4-5, 2005 Institute of Medicine Working Group Five: Immunology, Assay Standardization, and Correlates of Protection Research Recommendations

Develop, validate and standardize serologic tools for pandemic preparedness (1-2 yr) Improve neutralization assays for avian strains: Standard protocols, engineered inoculum (BSL-2), automation Improve HAI for detection of H5 antibodies Develop ELISA methods for HA subtypes Develop standardized purified/recombinant HA and NA proteins and reference serum panels Develop and standardize assays for anti-NA –Correlate subtype ELISA with ‘gold standard functional’ inhibition (NI) method

Seroepidemiologic research related to pandemic preparedness –Assess pre-pandemic antibodies to HA and NA –Investigate potential cross-protection provided by human anti-HA or anti-NA against avian strains Longer term goal: –Simpler serologic assays for field use

Investigate immune correlates of protection Goal: Characterize the human immune response to flu infection and vaccines using modern immunologic techniques Examples -Subtype-specific ELISA and neutralization assays for HA and NA to improve understanding of protection and cross- protection -Role of IgG/IgA in serum or at mucosal sites with specificity for HA or NA in protection -Use new methods for probing human immune responses to primary and secondary flu infection with non-pandemic strains in order to develop methods that can be applied immediately to studies in a pandemic setting -Characteristics of flu-specific memory T cells and B cells -Trafficking of immune cells to lung, mucosa, etc. -Cross-protective immunity by T cells against flu proteins

Apply new immunologic assays in prospective studies using clinical endpoints + viral shedding to define correlates of protection Improve understanding of consequences of antigenic ‘drift’ in H5 strains Use new tools to better understand immunopathogenesis in complex/fatal flu infection (epidemic and pandemic cases)

Additional research to evaluate flu vaccine immunity (2-5 yr) Goal: Develop panel of standardized immunologic assays for use in designing pandemic vaccines Compare capacities of inactivated, live attenuated and vectored vaccines to induce humoral, cellular and mucosal immunity, with primary and secondary vaccination and with varying routes of administration Immunogenicity and efficacy in infants, children, adults and the elderly Time to induction of protective response Persistence of immune response Generate experience with multiple pandemic vaccines to assess reactogenicity, immunogenicity, optimal dose and route of administration